Modern Chinese Medicine Group Co., Ltd. has issued a notice convening its 2026 Annual General Meeting (AGM) for 29 May 2026 at 10:00 a.m. in Shijiazhuang, Hebei. Eight ordinary resolutions and one special resolution will be put to vote.

Key proposals

1. 2025 Financial Statements • Shareholders will be asked to receive and adopt the audited consolidated financial statements and accompanying directors’ and auditor’s reports for the year ended 31 December 2025.

2. Board Composition • Executive Director Sun Xinlei and Independent Non-Executive Director Liu Ling are standing for re-election. • The board also seeks authority to set directors’ remuneration.

3. Auditor • Forvis Mazars CPA Limited is nominated for re-appointment as external auditor, with remuneration to be determined by the board.

4. Share Mandates • Share buy-back mandate: authority to repurchase up to 10% of the issued share capital (excluding treasury shares) during the mandate period. • General issuance mandate: authority to allot and issue up to 20% of issued shares, with an extension allowing the repurchase mandate’s unused portion (up to an additional 10%) to be added to the issuance limit.

5. Corporate Governance • The company proposes adopting a fully amended and restated set of Articles of Association consolidating changes outlined in the circular dated 28 April 2026.

Logistics and voting

• Shareholders recorded by 4:30 p.m. on 22 May 2026 will be entitled to attend and vote. The register of members will be closed from 26 May 2026 to 29 May 2026, both days inclusive. • Proxy forms must be lodged with Tricor Investor Services Limited by 10:00 a.m. on 27 May 2026 to be valid.

The board currently comprises three executive directors—Sun Xinlei, Zhang Hongli and Jia Yanru—and three independent non-executive directors—Liu Ling, Leung Tsz Wing and Wong Chi Kin.